IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities

Chimeric antigen receptor (CAR) modified T cells can induce complete remissions in patients with advanced hematological malignancies. Nevertheless, the efficacy is mostly transient and remains so far poor in the treatment of solid tumors. Crucial barriers to long-term CAR T cell success encompass lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis Christoph, Bezler, Valerie, Hartley, Jordan, Herr, Wolfgang, Abken, Hinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243527/
https://www.ncbi.nlm.nih.gov/pubmed/37287982
http://dx.doi.org/10.3389/fimmu.2023.1185618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243527/
https://www.ncbi.nlm.nih.gov/pubmed/37287982
http://dx.doi.org/10.3389/fimmu.2023.1185618

Ejemplares similares